Precise assessment of treatment response in glioblastoma during combined antiangiogenic and chemoradiation remains a challenge. In particular, early detection of treatment response by standard anatomical imaging is confounded by pseudo-response or pseudo-progression. Metabolic changes probed by MRSI are more specific for tumor physiology and less confounded by changes in blood-brain barrier permeability.
This abstract and the presentation materials are available to members only; a login is required.